Advertisement

Abdominal Radiology

, Volume 41, Issue 1, pp 33–41 | Cite as

Prognostic significance of parameters from pretreatment 18F-FDG PET in hepatocellular carcinoma: a meta-analysis

  • Da-Wei Sun
  • Lin An
  • Feng Wei
  • Lin Mu
  • Xiao-Ju Shi
  • Chuan-Lei Wang
  • Zheng-Wei Zhao
  • Teng-Fei Li
  • Guo-Yue LvEmail author
Review Paper

Abstract

Purpose

The prognostic value of 18F-deoxyglucose positron emission tomography (18F-FDG PET) on hepatocellular carcinoma (HCC) remains inconclusive. This study aims to investigate the prognostic role of pretreatment 18F-FDG PET on HCC patients by meta-analysis.

Methods

PubMed, Embase, Cochrane library, and Wanfang databases were searched until June 2015. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were synthesized by Stata 10.0, and the combined results were used as effective values.

Results

Twenty-two studies containing a total of 1721 patients were identified. According to random-effect model, meta-analysis results showed that high Tumor SUV/Liver SUV (Tsuv/Lsuv) ratio was significantly associated with poorer overall survival (OS) (HR = 2.04; 95% CI 1.50–2.79; P = 0.000) and poorer disease-free survival (HR = 7.17; 95% CI 3.58–14.36; P = 0.000); and high Tumor SUV (Tsuv) value was also correlated with poor OS (HR = 1.53; 95% CI 1.26–1.87; P = 0.000). Meanwhile, subgroup analysis results showed that the significant association above was not altered by study sample size, parameter cutoff value, analytic method, and follow-up period, but there was no significant association between Tsuv/Lsuv ratio and OS in patients who underwent resection (HR = 1.71; 95% CI 1.00–2.92; P = 0.052).

Conclusions

Both high Tsuv/Lsuv ratio and high Tsuv value are associated with poor prognosis in HCC patients. Therefore, pretreatment 18F-FDG PET is a useful tool in predicting the prognosis of HCC patients. More studies with explicit treatment modalities are required to investigate the prognostic value of pretreatment 18F-FDG PET on HCC patients.

Keywords

Hepatocellular carcinoma (HCC) 18F-deoxyglucose positron emission tomography (18F-FDG PET) Tumor SUV/Liver SUV (Tsuv/Lsuv) Tumor SUV (Tsuv) Prognosis Meta-analysis 

Notes

Acknowledgments

This work was supported by research funding from Jilin Provincial Science & Technology Department (No. 20130413021GH).

Compliance with Ethical Standards

Conflicts of Interest

None.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMedGoogle Scholar
  2. 2.
    Altekruse SF, McGlynn KA, Dickie LA, et al. (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology 55(2):476–482CrossRefPubMedGoogle Scholar
  3. 3.
    Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62(6):394–399CrossRefPubMedGoogle Scholar
  4. 4.
    Donswijk ML, Hess S, Mulders T, et al. (2014) [18F]Fluorodeoxyglucose PET/computed tomography in gastrointestinal malignancies. PET Clin 9(4):421–441CrossRefPubMedGoogle Scholar
  5. 5.
    Gauthé M, Richard-Molard M, Cacheux W, et al. (2015) Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 47(6):443–454CrossRefPubMedGoogle Scholar
  6. 6.
    Wang Z, Chen JQ, Liu JL, et al. (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19(29):4808–4817PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Maffione AM, Marzola MC, Capirci C, et al. (2015) Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol 204(6):1261–1268CrossRefPubMedGoogle Scholar
  8. 8.
    Li C, Lan X, Yuan H, et al. (2014) 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. Ann Nucl Med 28(5):436–446CrossRefPubMedGoogle Scholar
  9. 9.
    Jones M, Hruby G, Solomon M, et al. (2015) Diagnostic Value of <sup> 18 </sup> F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. [Epub ahead of print]Google Scholar
  10. 10.
    Lin CY, Chen JH, Liang JA, et al. (2011) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 81(9):2417–2422CrossRefPubMedGoogle Scholar
  11. 11.
    Parmar MK, Torri V, Stewart L (1988) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834CrossRefGoogle Scholar
  12. 12.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMedGoogle Scholar
  13. 13.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMedGoogle Scholar
  14. 14.
    Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634CrossRefGoogle Scholar
  15. 15.
    Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323(7306):224–228PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Song HJ, Cheng JY, Hu SL, et al. (2015) Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol 70(2):128–137CrossRefPubMedGoogle Scholar
  17. 17.
    Kim YK, Kim SH, Lee SD, et al. (2015) Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant Proc 47(3):686–693CrossRefPubMedGoogle Scholar
  18. 18.
    Kim MJ, Kim YS, Cho YH, et al. (2015) Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med 30(3):308–315PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Chang ZF, Song P, Wang MQ, et al. (2014) Value of 18F-FDG PET in preoperative TACE of hepatocellular carcinoma. Chin J Oncol 36(5):377–380Google Scholar
  20. 20.
    Xu ZQ, Zhang XS, Zhang LQ, et al. (2014) 18F-FDG PET/CT in predicting tumor recurrence for hepatocellular carcinoma after liver transplantation. Chin J Organ Transplant 35(6):341–344Google Scholar
  21. 21.
    Han JH, Kim DG, Na GH, et al. (2014) Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol 20(45):17132–17140PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Simoneau E, Hassanain M, Madkhali A, et al. (2014) (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol 21(4):e551–e556PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Kawamura E, Shiomi S, Kotani K, et al. (2014) Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 29(9):1722–1727CrossRefPubMedGoogle Scholar
  24. 24.
    Ahn SG, Jeon TJ, Lee SD, et al. (2013) A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol 39(9):964–973CrossRefPubMedGoogle Scholar
  25. 25.
    Detry O, Govaerts L, Deroover A, et al. (2015) Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 21(10):3049–3054PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Kim JW, Seong J, Yun M, et al. (2012) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 82(3):1172–1178CrossRefPubMedGoogle Scholar
  27. 27.
    Song MJ, Bae SH, IeR Yoo, et al. (2012) Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 18(25):3215–3222PubMedCentralPubMedGoogle Scholar
  28. 28.
    Kitamura K, Hatano E, Higashi T, et al. (2012) Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 19(1):156–162CrossRefPubMedGoogle Scholar
  29. 29.
    Kornberg A, Küpper B, Tannapfel A, et al. (2012) Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 18(1):53–61CrossRefPubMedGoogle Scholar
  30. 30.
    Shin DY, Han SW, Oh DY, et al. (2011) Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 68(1):165–175CrossRefPubMedGoogle Scholar
  31. 31.
    Kim BK, Kang WJ, Kim JK, et al. (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117(20):4779–4787CrossRefPubMedGoogle Scholar
  32. 32.
    Lee JW, Paeng JC, Kang KW, et al. (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50(5):682–687CrossRefPubMedGoogle Scholar
  33. 33.
    Paudyal B, Paudyal P, Oriuchi N, et al. (2008) Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 33(5):1047–1054PubMedGoogle Scholar
  34. 34.
    Yang SH, Suh KS, Lee HW, et al. (2006) The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 12(11):1655–1660CrossRefPubMedGoogle Scholar
  35. 35.
    Hatano E, Ikai I, Higashi T, et al. (2006) Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30(9):1736–1741CrossRefPubMedGoogle Scholar
  36. 36.
    Kong YH, Han CJ, Lee SD, et al. (2004) Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 10(4):279–287PubMedGoogle Scholar
  37. 37.
    Shiomi S, Nishiguchi S, Ishizu H, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96(6):1877–1880CrossRefPubMedGoogle Scholar
  38. 38.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMedGoogle Scholar
  39. 39.
    Ma WJ, Wang HY, Teng LS (2013) Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 11:212. doi: 10.1186/1477-7819-11-212 PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Niu ZS, Niu XJ, Wang M (2015) Management of hepatocellular carcinoma: predictive value of immunohistochemical markers for postoperative survival. World J Hepatol 7(1):7–27PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Zhou L, Rui JA, Wang SB, et al. (2014) Early recurrence in large hepatocellular carcinoma after curative hepatic resection: prognostic significance and risk factors. Hepatogastroenterology 61(135):2035–2041PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Da-Wei Sun
    • 1
  • Lin An
    • 2
  • Feng Wei
    • 1
  • Lin Mu
    • 3
  • Xiao-Ju Shi
    • 1
  • Chuan-Lei Wang
    • 1
  • Zheng-Wei Zhao
    • 1
  • Teng-Fei Li
    • 1
  • Guo-Yue Lv
    • 1
    Email author
  1. 1.Department of Hepatobiliary and Pancreatic SurgeryThe First Hospital of Jilin UniversityChangchunChina
  2. 2.Department of DermatologyChina-Japan Union Hospital of Jilin UniversityChangchunChina
  3. 3.Department of RadiologyThe First Hospital of Jilin UniversityChangchunChina

Personalised recommendations